Verification evidence is still being completed.
PDF / print export
Hamlet BioPharma
Lund, Sweden
- Verified lead
- Jakob Testad
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Oncology, Infection Therapeutics, Peptide Drugs, Bladder Cancer, and Clinical Development
- Review cycle
- May 2026
- Full address
- Hamlet BioPharma AB, Klinikgatan 32, SE-222 42 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Hamlet BioPharma March 2026 release confirming the Lund address.
- Editorial note
- Hamlet BioPharma is published because official company materials confirm current leadership, Lund operating address, and an active oncology and infection therapeutics platform.
Oncology, Infection Therapeutics, Peptide Drugs, Bladder Cancer, and Clinical Development
Official leadership disclosure, Official Lund address disclosure, Clinical-stage therapeutics platform claim
Hamlet BioPharma is published because official company materials confirm current leadership, Lund operating address, and an active oncology and infection therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Hamlet BioPharma
Oncology, Infection Therapeutics, Peptide Drugs, Bladder Cancer, and Clinical Development · Clinical-stage therapeutics platform
Hamlet BioPharma runs oncology drug development, anti-infective program development, and clinical program execution in Lund, Sweden.
- Lead
- Jakob Testad (verified ↗)
- Address
- Hamlet BioPharma AB, Klinikgatan 32, SE-222 42 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Oncology Drug Development · Anti-Infective Program Development · Clinical Program Execution
- Founded
- 2017
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Jakob Testad
Chief Executive Officer
Full addressHamlet BioPharma AB, Klinikgatan 32, SE-222 42 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Hamlet BioPharma March 2026 release listing the Lund address.
Open sourceClinical-stage therapeutics platform
Lund, Sweden. Oncology, Infection Therapeutics, Peptide Drugs, Bladder Cancer, and Clinical Development. Review completed on 22 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Lund address disclosure, Clinical-stage therapeutics platform claim
Oncology, Infection Therapeutics, Peptide Drugs, Bladder Cancer, and Clinical Development
Hamlet BioPharma is published because official company materials confirm current leadership, Lund operating address, and an active oncology and infection therapeutics platform.
Editorial note
Hamlet BioPharma is published because official company materials confirm current leadership, Lund operating address, and an active oncology and infection therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Oncology Drug Development
Anti-Infective Program Development
Clinical Program Execution
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Oncology and infection R&D systems
Program management infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Hamlet BioPharma located?
- Hamlet BioPharma operates from Hamlet BioPharma AB, Klinikgatan 32, SE-222 42 Lund, Sweden, Lund, Sweden.
- Who runs Hamlet BioPharma?
- Hamlet BioPharma is led by Jakob Testad, Chief Executive Officer. Verified 22 Mar 2026.
- What does Hamlet BioPharma do?
- Hamlet BioPharma runs oncology drug development, anti-infective program development, and clinical program execution in Lund, Sweden. Core capabilities: Oncology Drug Development, Anti-Infective Program Development, Clinical Program Execution.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.